Project Grant R43AI155218

This Project Grant awarded by the National Science Foundation (NSF) under the Mathematical and Physical Sciences (CFDA 47.049) program provides $418,579 to Cornell University to develop a new class of bioconjugates to improve the intracellular delivery of peptide-based proteolysis targeting chimeras (PEPTACs) for proteome-editing applications. The key objectives are to study the impact of conjugation site on antibody-PEPTAC conjugate (APC) transport and the release kinetics of PEPTAC-cell...

This $151,000 Project Grant, awarded on August 4, 2025, by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports transdisciplinary research focused on developing proteolysis targeting chimeras (PROTACs) for degrading poly(ADP-ribose) polymerase-1 (PARP-1) in diseased human cells. The research addresses limitations of existing PARP-1 inhibitors by designing a novel class of protein degraders based on...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

Paramita Therapeutics Inc. received a Phase I Small Business Innovation Research (SBIR) grant of $353,009 awarded on September 24, 2025, by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The project, titled "Novel Multivalent PSMA-Targeted Taxane-Conjugates for Bone Metastases in Prostate Cancer," is led by Principal Investigator Sang Van and will be completed by August 31, 2026. The research focuses on developing and synthesizing multivalent...

This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....

The National Science Foundation (NSF) awarded a $740,797 Project Grant under the Biological Sciences federal grant program (CFDA 47.074) to the Regents of the University of California, San Francisco (UCSF) to develop and test new methodologies for the rational design of minimalistic light-switchable single-domain proteins. The goal is to engineer these proteins to bind specifically to target proteins in only one photoswitchable chromophore state, allowing for precise spatial and temporal control...

Federal Project Grant Award Summary The National Cancer Institute awarded $593,338 to The University of Texas Health Science Center at San Antonio under the Cancer Treatment Research program (CFDA 93.395) on March 25, 2026, for the development of first-in-class AP2 associated kinase 1 (AAK1) proteolysis-targeting chimeras (PROTACs) targeting ovarian cancer treatment resistance. The project, extending through February 28, 2031, addresses a critical clinical challenge in ovarian cancer therapy:...

The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of engineered enzymes that can be activated to perform targeted modifications of cellular proteins. The $1,602,000 award to the Dana-Farber Cancer Institute, Inc. (DFCI) will fund research to design and apply novel autoinhibited enzymes that can toggle between inactive and active conformations in response...

Federal Project Grant Award Summary Onca Bio, Inc. received a $348,848 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350, effective September 15, 2025, with a completion date of September 14, 2026. The award funds research and development of segmented in vitro translation (SIVT) technology to advance macrocyclic peptide library diversity for drug discovery applications. Specifically, the project addresses current limitations in...